Cardiac catheterization and intervention in haemophilia patients: prospective evaluation of the 2009 institutional guideline. (18th March 2013)

• Record Type: Journal Article
• Authors: Tuinenburg, A.; Damen, S. A. J.; Ypma, P. F.; Mauser‐Bunschoten, E. P.; Voskuil, M.; Schutgens, R. E. G.
• Is Part Of: Haemophilia. Volume 19:Number 3(2013:May)
• Page Start: 370
• Page End: 377
• Publication Date: 2013-03-18
• Subjects: Hemophilia -- Periodicals; 616.1572005
• DOI: 10.1111/hae.12109
• Languages: English
• ISSNs: 1351-8216

Abstract

<abstract abstract-type="main" id="hae12109-abs-0001"> <title>Summary</title> <p>Ageing haemophilia patients are increasingly confronted with ischaemic heart disease (IHD). Treatment is complex because of the delicate equilibrium between bleeding and thrombosis. In 2009, we developed an institutional guideline on how to treat IHD in this patient population. The aim of this study was to evaluate feasibility and safety of this guideline. Haemophilia patients who underwent coronary angiography or percutaneous coronary intervention between January 2009 and June 2012 were included in the current case series. Nine diagnostic or therapeutic cardiac catheterizations were performed in six haemophilia patients. One patient with moderate haemophilia B was included, whereas the other patients had mild haemophilia A. In six of nine procedures, access to the circulation was gained via the radial artery. Only bare‐metal stents were implanted, after which dual antiplatelet treatment was given for at least 4 weeks. During cardiac catheterization/intervention and dual antiplatelet treatment, clotting factor levels were corrected. No thrombotic or clinically relevant bleeding complications occurred. In one patient, a low‐titre inhibitor recurred 10 months after catheterization. In‐stent restenosis was diagnosed in one patient. This case series indicates that treatment according to the guideline is feasible and safe. Furthermore, based on the case series and developments in new guidelines for non‐haemophilic patients with IHD, some adjustments on the 2009 guideline are proposed.</p> </abstract>